Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,600.00-0.34%ETH$2,697.97-0.63%GOLD$4,192.70+0.86%OIL$89.91+0.54%
Smart Investors Daily
SID Premium
LX

NASDAQ · LXEO

Lexeo Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$3.41

Down-$0.11 (-3.23%)

Updated Oct 6, 2026, 9:41 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
715.64M
P/E ratio
-3.74
Dividend yield
0.00%
52-week range
$2.98 – $8.00
Volume
1.86M
Avg. volume
1.28M

Price performance · LXEO

LXEO price history

1M range · 0 trading sessions · Daily adjusted prices

LXEO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LXEO news

The latest Smart Investors Daily articles mentioning LXEO.

Stock researchCompany · Overview

LXEO research

Overview

Company profile and research snapshot.

Company profile

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$19.83
Implied upside
—
Analysts
16
LXEO recent ratings
DateFirmRatingTarget
Sep 23, 2026Leerink PartnersOutperform—
Jun 25, 2026JP MorganOverweight—
May 11, 2026Chardan CapitalBuy—
Jan 13, 2026HC Wainwright & Co.Buy—
Jan 13, 2026Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1) and cross the blood-brain barrier.

Yahoo · Sep 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By